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Abstract
Vitamin D deﬁciency is common in advanced liver disease but its clinical signiﬁcance remains controversial. The aim of this study
was to examine the correlation of 25-hydryoxyvitamin D levels with liver disease severity and calcium levels in adults with
cirrhosis. This cross-sectional study included 180 adults with cirrhosis enrolled in a clinical cohort study at a single university hos-
pital. The mean age was 58.8 (±9.2) years, and cirrhosis was attributed to alcohol use in 27.2%, hepatitis C in 35.0%, non-alcoholic
steatohepatitis in 27.2%, and both alcohol and hepatitis C in 10.6%. The median model for end-stage liver disease-sodium
(MELD-Na) score was 12.0 (interquartile range 9.0–16.0), and mean serum albumin levels were 3.4 (±0.7) gm/dl. Median
serum 25-hydroxyvitamin D levels were 28.0 (interquartile range 20–38) ng/mL, with 16 patients (8.9%) having levels <12 ng/ml
and 43 (23.9%) with 25(OH)D levels <20 ng/ml. No correlation was noted between levels of 25-hydroxyvitamin D and albumin-
corrected calcium in the total group and in groups stratiﬁed by vitamin D supplementation. In contrast, both serum albumin
(r = 0.32; P < 0.001) and MELD-Na scores were signiﬁcantly correlated with 25-hydroxyvitamin D levels (r = –0.29; P < 0.001).
Correlations between 25-hydroxyvitamin D levels and serum albumin (r = −0.39; P < 0.001) and MELD-Na scores did not
change substantially after excluding 67 patients receiving vitamin D supplementation (r = −0.33; P = 0.009). In conclusion, total
25-hydroxyvitamin D levels correlate inversely with liver disease severity in adults with cirrhosis.
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Introduction
Vitamin D impacts bone mineralization and calcium homeos-
tasis by increasing intestinal calcium absorption (1, 2). With-
out vitamin D, only 10% to 15% of dietary calcium and less
than 60% of dietary phosphate is absorbed (3). The liver
plays an important role in vitamin D metabolism. Vitamins
D2 and D3 derived from food and supplements, and vitamin
D3 obtained via sunlight exposure, undergo hydroxylation in
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the liver forming 25-hydroxyvitamin D [25(OH)D], which
is then hydroxylated mainly in the kidneys to 1,25 dihydrox-
yvitamin D [1,25(OH)2D], the biologically active form of
vitamin D. The liver also produces bile acids, which are neces-
sary for optimal gastrointestinal absorption of vitamin D
obtained from foods or supplements (4). Vitamin D metabo-
lites undergo enterohepatic circulation, and in the setting of
liver dysfunction, impaired excretion of vitamin D metabo-
lites may inhibit production or activation of 25(OH)D (5).
Several previous studies showed a high prevalence of low
25(OH)D levels among adults with cirrhosis (6–9), and low
25(OH)D levels have been hypothesized to play a role in
the progression of several liver diseases (10–14). However,
it is possible that low 25(OH)D levels simply reﬂect liver dis-
ease severity because hepatocytes produce vitamin D binding
globulin (VDBG), the major vehicle for vitamin D transport.
Over 90% of 25(OH)D circulates bound to VDBG and
albumin, while the rest circulates unbound or free (15). Total
25(OH)D levels measured in clinical practice mainly reﬂect
25(OH)D bound to VDBG and albumin (16). Thus, 25(OH)D
levels as currently measured in clinical practice may be low in
patients with hepatic synthetic dysfunction due to low serum
levels of VDBG and albumin (9, 17).
In the current study, we evaluated data from a cohort of
adults with cirrhosis receiving care at a single academic insti-
tution. The aim of the study was to evaluate the association of
25(OH)D levels with liver disease severity measures and albu-
min-corrected serum calcium levels in patients with cirrhosis.
Liver disease severity was assessed with serum albumin levels
(18) and the modeling end-stage liver disease-sodium score
(MELD-Na) (19). The original MELD score predicted prog-
nosis in patients with cirrhosis based on kidney function and
dialysis requirements, serum bilirubin, and the international
normalized ratio (INR). In recognition of the independent
association between serum sodium and transplant waitlist
mortality for patients with cirrhosis (19–23), the Organ Pro-
curement and Transplantation Network began incorporating
the MELD-Na score for prioritizing transplants based on
liver disease severity in 2016 (24). This study also examined
the proportion of 25(OH)D variance attributed to the
MELD-Na score, serum albumin levels, and demographic vari-
ables and the use of vitamin D supplements. We hypothesized
that 25(OH)D levels are inversely correlated with measures of
liver disease severity but not albumin-corrected calcium levels
in patients with advanced liver disease. We further hypothesized
that liver disease severity accounts for a substantial proportion
of the variance in 25(OH)D levels in adults with cirrhosis.
Methods
Study population
This cross-sectional study included patients with cirrhosis
receiving hepatology care at Loyola University Medical
Center, a large, urban academic medical institution. Patients
with cirrhosis were enrolled in a cohort study designed to
examine the determinants of liver disease progression during
a routine clinic visit from August 29, 2013 to January 28,
2015 and clinical, biochemical, and radiological tests were
performed. The study was approved by the Loyola University
Chicago Institutional Review Board, and all patients pro-
vided written informed consent. Diagnosis of cirrhosis was
based on clinical and radiological examination or liver histol-
ogy. Overall, a total of 456 adults with cirrhosis enrolled
in the main cohort study. We excluded 68 participants
with cirrhosis from hepatitis B infection, hemochromatosis,
Wilson’s disease, or autoimmune hepatitis, due to the low
number of participants with each of these disorders. Among
the 388 patient participants with alcohol (ETOH)-related,
Table 1. Demographics of the patient participants (N = 180)
Age (years) 58.8 ± 9.2
Male (%) 53.3
Race (%)
White
African American
Asian
Paciﬁc Islander
Unknown
76.7
8.3
1.1
0.5
13.3
Cirrhosis etiology (%)
Alcohol
HCV
NASH
Both alcohol and HCV
27.2
35.0
27.2
10.6
BMI (kg/m2) 31.8 ± 7.6
Calcium (mg/dl) 9.1 ± 0.6
Corrected calciuma (mg/dl) 9.5 ± 0.5
Albumin (g/dl) 3.4 ± 0.7
International normalized ratio 1.3 ± 0.3
Creatinine (mg/dl) 1.1 ± 0.8
Sodium (mEq/l) 137.7 ± 3.5
Total bilirubinb (mg/dl) 1.2 (0.7–2.1)
MELD-Na scoreb 12.0 (9.0–16.0)
Vitamin Db (ng/ml) 28.0 (20.0–38.0)
Vitamin D supplementation (%) 37.2
Calcium supplementation (%) 22.8
Data shown as frequency (%) or mean ± standard deviation; aCor-
rected calcium = measured total calcium in mg/dL + [0.8 × (4 – albu-
min in g/dl)]; bData shown as median (interquartile range); BMI =
bodymass index,HCV=hepatitis C virus,NASH=non-alcohol stea-
tohepatitis, MELD-Na = modeling end-stage liver disease-sodium
score (19).
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hepatitis C virus (HCV), or non-alcohol steatohepatitis
(NASH)-related cirrhosis, we excluded 184 with missing
data on 25(OH)D levels and 24 with missing serum calcium
and albumin levels measured at the time when vitamin D
was measured. This left a total of 180 patient participants
included in the analyses.
Disease etiology, demographics
Information on demographics was obtained using standar-
dized questionnaires, while the primary etiology of liver dis-
ease and presence of co-morbidities were obtained from the
electronic medical record. Diabetes was deﬁned as a physi-
cian diagnosis of diabetes and/or use of glucose-lowering
medications. At the clinic visit, weight was measured without
shoes to the nearest 0.1 kg using a standard balance, and
height was measured using a stadiometer without shoes.
Body mass index (BMI) was deﬁned as weight in kilograms
divided by the height in meters squared. Information on med-
ication use and vitamin D supplementation, including ergo-
calciferol or cholecalciferol, and calcium supplementation
was obtained from the medication list in the electronic med-
ical record at the time of enrollment.
Laboratory parameters
Non-fasting blood specimens were collected during a clinic
visit and were sent immediately to the Loyola laboratory
for measurement of routine clinical measurements. Serum
25(OH)D was measured using the chemiluminescent immu-
noassay. Serum albumin, creatinine, and total bilirubin
were measured using a colorimetric method, and calcium
Table 2. Characteristics of patient participants by serum 25-hydroxyvitamin D [25(OH)D] groups
25(OH)D Groups
<12 ng/ml 12–19.9 ng/ml 20–29.9 ng/ml ≥30 ng/ml Overall P-value
N 16 27 58 79
Age 55.6 ± 10.2 56.8 ± 9.1 58.7 ± 8.6 60.2 ± 9.3 0.2
Male (%) 53.6 66.7 52.7 58.5 0.4
BMI (kg/m2) 30.4±6.5 32.3±8.5 32.2 ± 6.6 31.6 ± 8.2 0.9
25(OH)D (ng/ml)a 10.0 (7.0–11.0) 17.0 (15.0–19.0)* 25.0 (22.0–27.0)* 39 (32.3–47.0)* <0.001
MELD-Naa 20.0 (17.0–28.0) 14.0 (9.5–16.5)* 12.0 (9.0–15.0)* 10.5 (8.0–15.0)* <0.001
Calcium (mg/dl) 8.5±0.5 9.0±0.4 9.0 ± 0.6 9.2 ± 0.6 0.003
Corrected calciumb
(mg/dl)
9.4±0.1 9.6±0.1* 9.5 ± 0.1* 9.6 ± 0.1* 0.7
Albumin (g/dl) 2.86±0.2 3.20±0.1* 3.29 ± 0.1* 3.60 ± 0.1* <0.001
International
normalized ratio
1.6±0.6 1.3±0.3* 1.2 ± 0.3)* 1.2 ± 0.2* <0.001
Total bilirubin (mg/dl) 2.4 (1.0–3.6) 1.7 (1.0–2.9)* 1.2 (0.7–2.1)* 1.0 (0.7–2.1)* <0.001
Sodium (mEq/L) 133.9±5.4 137.8±3.9* 138.1 ± 3.0* 138.2 ± 2.6* <0.001
Cirrhosis etiology (%)
HCV
ETOH
ETOH and HCV
NASH
18.8
43.8
18.8
18.8
25.9
37.0
11.2
25.9
42.6
24.6
3.3
29.5
34.6
22.2*
13.6
29.6
0.6
0.05
0.2
0.2
Vitamin D
supplementation (%)
31.3 25.9 34.5 44.3 0.3
Calcium
supplementation (%)
25.0 14.8 20.7 26.6 0.6
Data shown as frequency (%) or mean ± standard deviation; aData shown as median (interquartile range); BMI = body mass index, HCV =
hepatitis C virus, MELD-Na = modeling end-stage liver disease score (19), NASH = non-alcohol steatohepatitis; bCorrected calcium = measured
total calcium in mg/dL + [0.8 × (4 – albumin in g/dl)]; *P < 0.01 compared to group with 25(OH)D <12 ng/ml.
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was measured using indirect ion selective electrodes. Blood
reference range values were as follows: serum calcium
(8.5–10.5 mg/dl), serum 25(OH)D (20–80 ng/ml), and serum
albumin (3.6–5.0 g/dl). The following equation was used
to calculate corrected calcium levels: corrected Ca (mg/dl) =
measured total calcium in mg/dl + [0.8 × (4 – albumin in
g/dl)]. Serum sodium was measured using an ion-speciﬁc elec-
trode. The MELD-Na score was calculated as a measure of
liver disease severity using the serum creatinine, total bilirubin,
INR, and serum sodium measured during the clinic visit when
25(OH)D was also measured (19).
Statistical analyses
We used STATA/IC 13.1 (StataCorp LP, College Station,
TX, USA) to perform all statistical analyses. Normality for
variables was examined using the Shapiro–Wilk test. Patients
were categorized based on their 25(OH)D levels (25), and
then summary statistics for key baseline characteristics were
compared by vitamin D categories. Mean and median values
are shown for variables with and without normal distribu-
tions, respectively, and frequencies were reported for catego-
rical variables. Continuous variables were compared using
ANOVA, and categorical variables were compared using
the Fishers exact test. To compare variables without a normal
distribution across groups, the variable was log transformed
and then compared using ANOVA. If the overall F-test
was statistically signiﬁcant, then each vitamin D category
was compared to the lowest category using an unpaired
t-test. The level of statistical signiﬁcance was set as P < 0.01
to account for multiple comparisons (3 vitamin D categories
compared to the lowest category).
Scatterplots of serum levels of corrected calcium, albumin,
and MELD-Na scores by 25(OH)D levels were examined.
Spearman rank correlation coefﬁcients were calculated to
quantify the correlation between corrected calcium and
albumin levels and MELD-Na scores in the total group and
after stratifying by vitamin D and calcium supplementation.
Locally weighted regression smooth scatterplot (LOESS)
lines were ﬁtted to characterize the association between
25(OH)D and liver disease severity measures (MELD-Na
and serum albumin levels) and serum calcium levels, and all
associations were found to be linear. Linear regression models
were then used to examine the adjusted association of serum
albumin and MELD-Na scores with total 25(OH)D levels.
The models adjusted for age, sex, race (white vs. non-white),
BMI, liver disease etiology (ETOH vs. other causes), and
vitamin D supplementation use (yes/no). These covariates
Figure 1. Scatterplot of corrected serum calcium levels by 25-hydroxyvitamin D [25(OH)D] levels in the total group of patient
participants with cirrhosis (n = 180).
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were selected because they may inﬂuence vitamin D levels
(2, 6). Due to the strong correlation betweenMELD-Na scores
and serumalbumin levels (r =−0.58; P< 0.001), separatemodels
were created to examineMELD-Naand serumalbumin levels as
explanatory variables.
Results
Demographic data for the selected cohort are displayed in
Table 1. Most of the patient participants were white
(76.7%), and male (53.3%) and the mean age was 58.8 ± 9.2
years. Cirrhosis etiology was ETOH in 27.2%, HCV in
35.0%, NASH in 27.2%, and both ETOH and HCV in
10.6%. The median MELD-Na score was 12.0 (interquartile
range 9.0–16.0) and mean serum albumin level was 3.4 ±
0.7 gm/dl. Overall, 37.2% and 22.8% were taking vitamin D
and calcium supplements, respectively, and 26.0% were tak-
ing both. The dose of vitamin D and type of vitamin D varied.
A total of 18 patients were taking ergocalciferol 50,000 inter-
national units (IU) weekly, and 28 patients were taking
cholecalciferol with doses ranging from 400 to 2000 IU
daily. Twenty-one patients were taking over the counter
vitamin D3 supplements with doses ranging from 400 to
1200 IU daily. Among the patients taking calcium supple-
ments, the median supplemental calcium intake was 1000 IU
(interquartile range 615–1200 IU).
Figure 2. Scatterplot of relationship of serum 25-hydroxyvitamin D [25(OH)D] and serum-corrected calcium in patients receiving
both vitamin D and calcium supplementation (n = 37) (top) and in patients not receiving vitamin D or calcium supplementation
(n = 109) (bottom).
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The median serum 25(OH)D level was 28.0 ng/ml (inter-
quartile range 20–38 ng/ml), and 16 patients (8.9%) had
25(OH)D levels <12 ng/ml and 43 (23.9%) had 25(OH)D
levels <20 ng/ml. Table 2 shows the characteristics of the par-
ticipants by 25(OH)D groups. Overall, serum calcium and
albumin levels generally increased and MELD-Na scores
decreased across increasing 25(OH)D groups. In contrast,
corrected serum calcium levels did not differ signiﬁcantly
across 25(OH)D groups. Vitamin D supplementation was
similar across the 25(OH)D groups.
No correlation was noted between albumin-corrected cal-
cium and 25(OH)D levels in the total group (Figure 1) or in
groups stratiﬁed by vitamin D and calcium supplementation
use (Figure 2). In contrast, both serum albumin (r = 0.32;
P < 0.001) and MELD-Na scores (r = –0.29; P < 0.001)
were signiﬁcantly correlated with 25(OH)D levels (Figure 3).
After excluding 67 patients receiving vitamin D supplementa-
tion, correlations between 25(OH)D and serum albumin (r =
0.39; P < 0.001) and MELD-Na scores (r = −0.33; P = 0.009)
did not change substantially. The results of the linear regression
models are shown in Table 3. Serum albumin and MELD-Na
scores alone accounted for 9% and 17% of the variance
in log-transformed 25(OH)D levels, respectively. Serum albu-
min levels combined with all covariates and MELD-Na
scores combined with all covariates accounted for 12.6%
and 23.1% of the variance of log-transformed 25(OH)D
Figure 3. Scatterplots of 25-hydroxyvitamin D [25(OH)D] levels by serum albumin levels (top) and by MELD-Na scores
(bottom) in patients with cirrhosis (n = 180).
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levels, respectively. In the linear regression models, only
serum albumin andMELD-Na scores were signiﬁcantly asso-
ciated with log-transformed 25(OH)D levels.
Discussion
In this single center study, we show that low vitamin D levels
are common in patients with cirrhosis, as demonstrated in
previous studies (6, 7, 9, 26–28). However, the prevalence
of low vitamin levels, deﬁned as 25(OH)D levels <20 ng/ml,
was less than many previous studies (7, 26–28), which may
be due to higher use of vitamin D supplementation and
lower disease severity in our patient population. One study
of 202 pre-liver transplant patients reported that 25(OH)D
levels were less than 20 ng/ml among 84% of patients prior
to liver transplantation, with 13% having undetectable con-
centrations (9). Our study also conﬁrms the ﬁndings of several
previous studies that demonstrated an inverse correlation
between 25(OH)D levels and measures of liver disease sever-
ity (6, 9, 26, 29–31), such as the Child Pugh score and MELD
score, and a positive correlation with serum albumin concen-
trations. Another important ﬁnding of the present study was
that low 25(OH)D levels were not associated with serum cal-
cium levels in patients with cirrhosis. In fact, no patient had
an albumin-corrected serum calcium value <8.5 mg/dl.
While the relationship between cirrhosis and vitamin D
deﬁciency is well-described (6, 28), it remains uncertain how
vitamin D deﬁciency impacts calcium homeostasis in patients
with cirrhosis. One study of 158 pre-transplant patients with
end-stage liver disease examined the serum levels of calcium
and intact parathyroid hormone levels (iPTH) across the
spectrum of 25(OH)D levels. This study found no differences
in mean serum iPTH and corrected calcium levels among
these patients (32). The lack of a correlation between calcium,
iPTH, and total 25(OH)D levels may be due to the fact
that total 25(OH)D includes a large fraction of 25(OH)D
that is tightly bound to VDBG, and relatively small amounts
of 25(OH)D bound loosely to albumin and 25(OH)D circu-
lating freely or unbound. It has been hypothesized that
the 25(OH)D circulating tightly bound to VDBG is not as
clinically important as the vitamin D circulating free or
loosely bound to albumin, known as bioavailable vitamin
D (16, 33). The existence of compensatory mechanisms for
vitamin D homeostasis in advanced liver disease was sug-
gested by ﬁndings from a small study, which showed signiﬁ-
cantly lower total 25(OH)D levels among 24 patients with
cirrhosis compared to 107 healthy controls while measured
free 25(OH)D levels were higher among the adults with cir-
rhosis (33). A study of liver transplant recipients, most of
who were vitamin D deﬁcient pre-transplant, found that
total and free 25(OH)D along with VDBG increased after
transplantation (9). While vitamin D has been hypothesized
to modulate inﬂammation and ﬁbrosis in liver disease
(26, 34), it is not clear whether lower vitamin D levels in
patients with cirrhosis are a cause or an effect of liver disease
progression. The possibility that low vitamin D levels contri-
bute to liver disease progression is intriguing, although the
available data have not established a clear causal association.
It is also possible that low total vitamin D levels simply
reﬂect the severity of liver disease. As liver disease worsens,
hepatic production of VDBG decreases and total measured
25(OH)D levels are consequently lower. Indeed, our study
Table 3. Results of linear regression models with log transformed 25(OH)D levels as dependent variable
Model with MELD-Na +R2 Model with Albumin +R2
Beta (SE) P-value 0.23 Beta (SE) P-value 0.13
Albumin – 0.23 (0.23) <0.001
MELD −0.04 (0.01) <0.001 –
Age 0.01 (0.004) 0.07 0.01 (0.005) 0.8
Sex −0.04 (0.08) 0.7 −0.05 (0.08) 0.5
White race vs.
non-white race
0.13 (0.10) 0.2 0.07 (0.09) 0.4
BMI (kg/m2) −0.01 (0.01) 0.2 0.0001 (0.006) 0.9
Liver disease due to
alcohol vs. other
0.02 (0.1) 0.8 −0.03 (0.09) 0.8
Vitamin D
supplementation
0.14 (0.08) 0.1 0.10 (0.08) 0.2
MELD-Na = modeling end-stage liver disease score(19); SE = standard error; R2 indicates the amount of variance in log transformed 25(OH)D
levels explained by the model; beta represents the change in log transformed 25(OH)D levels with every unit increase in the predictor variable after
adjustment for all variables in the linear regression model.
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showed a signiﬁcant and inverse correlation between 25(OH)
D levels and MELD-Na scores. These ﬁndings are supported
by previous studies, which also showed signiﬁcant and inverse
correlations between 25(OH)D levels and liver disease
measures (26, 28).
This study includes a large number of adults with cirrhosis,
and the 25(OH)D and serum calcium levels were evaluated as
part of a routine clinical examination. The study is limited by
lack of information on levels of 1,25-dihydroxyvitamin D
levels, the active form of vitamin D, and VDBG. We also
did not have information on other markers of vitamin D
homeostasis such as iPTH levels. Serum calcium levels may
be affected by several factors other than vitamin D, including
serum iPTH levels and dietary calcium intake. While we did
have information on calcium supplement use, information on
dietary calcium intake was not collected. In addition, we did
not have measures of patient compliance with the vitamin D
and calcium supplements.
Conclusion
This study shows that total 25(OH)D levels correlate
inversely with liver disease severity in adults with cirrhosis,
while no correlation exists between 25(OH)D levels and
albumin-corrected serum calcium levels. The ﬁndings from
this study along with other previous studies support the exis-
tence of compensatory mechanisms for maintaining calcium
homeostasis in patients with advanced liver diseases. Future
studies should examine changes in measures of vitamin D
and vitamin D homeostasis with vitamin D supplementation
in patients with cirrhosis. Such information may help eluci-
date whether vitamin D supplementation interferes with
existing compensatory mechanisms for maintaining vitamin
D homeostasis in the setting of advanced liver disease.
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